Clinical Trial Update: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 study of alisertib plus romidepsin in relapsed or refractory B-cell and T-cell lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Mature T-cell Lymphoma
• Natural Killer Cell Lymphoma

Drugs mentioned

• Alisertib (alisertib)
• Romidepsin (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED